Literature DB >> 24429160

Impact of B-type natriuretic peptide on short-term clinical outcomes following transcatheter aortic valve implantation.

Crochan J O'Sullivan1, Stefan Stortecky, Dik Heg, Peter Jüni, Stephan Windecker, Peter Wenaweser.   

Abstract

AIMS: We aimed to assess the impact of B-type natriuretic peptide (BNP) on short-term outcomes in patients undergoing transcatheter aortic valve implantation (TAVI). METHODS AND
RESULTS: Of 500 consecutive patients with severe aortic stenosis undergoing TAVI at our institution, we studied 340 patients who had a BNP assessment prior to TAVI. Patients were divided into tertiles - low: BNP ≤201 pg/mL (n=114), mid: BNP 202-595 pg/mL (n=113) and high: BNP ≥596 pg/mL (n=113). The primary endpoint was all-cause mortality, cardiac death and major adverse cardiac and cerebrovascular events (MACCE; death, major stroke and myocardial infarction) at 30 days. Compared with low tertile, high tertile patients were at higher baseline surgical risk (STS score 5.5±3.0 vs. 7.4±4.1, p=0.002). On echocardiography, high tertile patients had smaller valve areas (0.74±0.21 vs. 0.66±0.23 cm², p=0.008), higher left ventricular (LV) mass indices (123.40±33.66 vs. 168.22±47.96 g/m², p<0.001) and lower LV ejection fractions (61.59±7.18 vs. 42.65±15.41%, p<0.001) as compared with low tertile patients. At 30 days, a significantly higher incidence of death (hazard ratio [HR] 7.41, p=0.001) cardiac death (HR 5.82, p=0.006) and MACCE (HR 9.04, p<0.001) was observed among high as compared to low tertile patients.
CONCLUSIONS: In TAVI patients, higher BNP values at baseline are associated with an increased risk for an adverse event periprocedurally and after 30 days, respectively.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24429160     DOI: 10.4244/EIJV10I10A200

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  10 in total

1.  Predictive value of preprocedural procalcitonin for short- and long-term mortality after transfemoral transcatheter aortic valve implantation.

Authors:  Stanislav Keranov; Won-Keun Kim; Mani Arsalan; Matthias Renker; Till Keller; Timm Bauer; Oliver Dörr; Holger M Nef; Luise Gaede; Helge Möllmann; Thomas Walther; Christian W Hamm; Christoph Liebetrau
Journal:  Heart Vessels       Date:  2019-06-07       Impact factor: 2.037

Review 2.  Transcatheter aortic valve replacement in patients with severe aortic stenosis and heart failure.

Authors:  Chirag Bavishi; Dhaval Kolte; Paul C Gordon; J Dawn Abbott
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

3.  Evaluation of CA125 and NT-proBNP values in patients undergoing transcatheter aortic valve implantation.

Authors:  Hüseyin Ayhan; Hacı Ahmet Kasapkara; Tahir Durmaz; Telat Keleş; Cenk Sarı; Serdal Baştuğ; Kemal Eşref Erdoğan; Nihal Akar Bayram; Emine Bilen; Murat Akçay; Engin Bozkurt
Journal:  J Geriatr Cardiol       Date:  2015-03       Impact factor: 3.327

4.  Elevation of B-Type Natriuretic Peptide at Discharge is Associated With 2-Year Mortality After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis: Insights From a Multicenter Prospective OCEAN-TAVI (Optimized Transcatheter Valvular Intervention-Transcatheter Aortic Valve Implantation) Registry.

Authors:  Kazuki Mizutani; Masahiko Hara; Shinichi Iwata; Takashi Murakami; Toshihiko Shibata; Minoru Yoshiyama; Toru Naganuma; Futoshi Yamanaka; Akihiro Higashimori; Norio Tada; Kensuke Takagi; Motoharu Araki; Hiroshi Ueno; Minoru Tabata; Shinichi Shirai; Yusuke Watanabe; Masanori Yamamoto; Kentaro Hayashida
Journal:  J Am Heart Assoc       Date:  2017-07-14       Impact factor: 5.501

5.  B-type natriuretic peptide is associated with remodeling and exercise capacity after transcatheter aortic valve replacement for aortic stenosis.

Authors:  Kimi Sato; Arnav Kumar; Amar Krishnaswamy; Stephanie Mick; Milind Y Desai; Brian P Griffin; Samir R Kapadia; Zoran B Popović
Journal:  Clin Cardiol       Date:  2018-12-31       Impact factor: 2.882

6.  Biomarkers Associated with Mortality in Aortic Stenosis: A Systematic Review and Meta-Analysis.

Authors:  Madeline White; Ranu Baral; Alisdair Ryding; Vasiliki Tsampasian; Thuwarahan Ravindrarajah; Pankaj Garg; Konstantinos C Koskinas; Allan Clark; Vassilios S Vassiliou
Journal:  Med Sci (Basel)       Date:  2021-05-17

7.  Periprocedural Changes of NT-proBNP Are Associated With Survival After Transcatheter Aortic Valve Implantation.

Authors:  Hatim Seoudy; Johanne Frank; Markus Neu; Nathalie Güßefeld; Yannic Klaus; Sandra Freitag-Wolf; Moritz Lambers; Georg Lutter; Astrid Dempfle; Ashraf Yusuf Rangrez; Christian Kuhn; Norbert Frey; Derk Frank
Journal:  J Am Heart Assoc       Date:  2019-02-05       Impact factor: 5.501

8.  Utility of High-Sensitivity and Conventional Troponin in Patients Undergoing Transcatheter Aortic Valve Replacement: Incremental Prognostic Value to B-type Natriuretic Peptide.

Authors:  Yukari Kobayashi; Juyong B Kim; Kegan J Moneghetti; Michael Fischbein; Anson Lee; Claire A Watkins; Alan C Yeung; David Liang; Mehmet O Ozen; Utkan Demirci; Raffick Bowen; William F Fearon; Francois Haddad
Journal:  Sci Rep       Date:  2019-10-17       Impact factor: 4.379

9.  Baseline NT-proBNP Accurately Predicts Symptom Response to Transcatheter Aortic Valve Implantation.

Authors:  Christopher J Allen; Jubin Joseph; Tiffany Patterson; Matthew Hammond-Haley; Hannah Z R McConkey; Bernard D Prendergast; Michael Marber; Simon R Redwood
Journal:  J Am Heart Assoc       Date:  2020-11-26       Impact factor: 5.501

10.  B-type natriuretic peptide ability to predict mortality after transcatheter aortic valve replacement.

Authors:  Heidi Lehtola; Jarkko Piuhola; Matti Niemelä; Tuomas Tauriainen; Juhani Junttila; Timo Mäkikallio; Tatu Juvonen; Fausto Biancari
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2022-01-01       Impact factor: 2.160

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.